<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Etiology and treatment of calcipenic rickets in children</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Etiology and treatment of calcipenic rickets in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Etiology and treatment of calcipenic rickets in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas Carpenter, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph I Wolfsdorf, MD, BCh</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Calcipenic rickets comprises a group of disorders in which supply of calcium or its intestinal absorption is too low to match the calcium demands imposed by bone growth.</p><p>The most common cause of calcipenic rickets is dietary deficiency of vitamin D and/or calcium, resulting in an inadequate supply of calcium for bone mineralization. Alternatively, calcipenic rickets may be caused by decreased vitamin D activity (eg, lack of conversion to the active metabolite or resistance to the active metabolite) or secondary causes of reduced intestinal calcium absorption. Patients with calcipenic rickets usually have secondary hyperparathyroidism and characteristic changes of the growth plates and metaphyseal bone.</p><p class="headingAnchor" id="H33082307"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>The clinical features of rickets and diagnostic evaluation to determine the cause of rickets are discussed in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/5856.html" rel="external">"Overview of rickets in children"</a>.)</p><p>In brief, patients with calcipenic rickets are identified by elevated parathyroid hormone (PTH) and normal or low serum inorganic phosphorus (<a class="graphic graphic_algorithm graphicRef79880" href="/z/d/graphic/79880.html" rel="external">algorithm 1</a>). Serum calcium levels are usually low in calcipenic rickets but may be normal in early stages of the disease due to a compensatory increase in PTH. Measurement of serum 25-hydroxyvitamin D (25OHD) helps to categorize the disorder into one of the following subcategories, which are discussed in detail in this topic review (<a class="graphic graphic_algorithm graphicRef80602" href="/z/d/graphic/80602.html" rel="external">algorithm 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Dietary vitamin D deficiency (the "classic" form of rickets)</p><p class="bulletIndent1"><span class="glyph">●</span>Dietary calcium deficiency</p><p class="bulletIndent1"><span class="glyph">●</span>Deficiency of 1-alpha-hydroxylase, the enzyme that converts 25OHD to its active metabolite, 1,25-dihydroxyvitamin D (1,25[OH]<sub>2</sub>D)</p><p class="bulletIndent1"><span class="glyph">●</span>25-hydroxylase deficiency</p><p class="bulletIndent1"><span class="glyph">●</span>Hereditary resistance to vitamin D (HRVD), caused by dysfunction of the vitamin D receptor</p><p></p><p>Chronic renal failure can also alter vitamin D metabolism and cause calcipenic rickets. This mechanism is discussed in separate topic reviews. (See  <a class="medical medical_review" href="/z/d/html/1969.html" rel="external">"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)"</a> and  <a class="medical medical_review" href="/z/d/html/2033.html" rel="external">"Overview of vitamin D", section on 'Metabolism'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">NUTRITIONAL RICKETS</span><span class="headingEndMark"> — </span>Classic forms of nutritional rickets, caused by inadequate intake of vitamin D and/or calcium, continues to be prevalent in many parts of the world and often is associated with other conditions [<a href="#rid1">1</a>]. In Ethiopia, for example, rickets affects a large proportion of children who present with severe infectious diseases [<a href="#rid2">2</a>].</p><p>Although infrequent, nutritional rickets can also occur as a result of phosphate deprivation [<a href="#rid3">3</a>]. This may occur in premature infants who receive breast milk as their sole source of nutrition and reflects the relatively low phosphate content of breast milk. It has also been described in a case series of young children with complex disease who were fed an elemental, amino acid-based formula, probably because of low phosphate bioavailability [<a href="#rid4">4</a>]. For this reason, serum phosphate levels should be monitored in such settings. These and other types of phosphopenic rickets are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5856.html" rel="external">"Overview of rickets in children", section on 'Phosphopenic rickets'</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Vitamin D deficiency</span></p><p class="headingAnchor" id="H4"><span class="h3">Etiology</span><span class="headingEndMark"> — </span>An infant's vitamin D status depends upon the amount of vitamin D transferred from the mother prenatally and upon the amount of vitamin D ingested or produced by the skin during exposure to ultraviolet light postnatally [<a href="#rid5">5</a>]. Maternofetal transfer of vitamin D is mostly in the form of 25-hydroxyvitamin D (25OHD), which readily crosses the placenta [<a href="#rid6">6</a>]. The half-life of 25OHD in an infant is approximately two to three weeks [<a href="#rid5">5</a>]. Thus, the serum concentration of vitamin D falls rapidly after birth unless additional sources are available. (See  <a class="medical medical_review" href="/z/d/html/14590.html" rel="external">"Vitamin D insufficiency and deficiency in children and adolescents", section on 'Pathogenesis and risk factors'</a>.)</p><p>Vitamin D deficiency rickets typically presents between three months and three years of age, when growth rates (and calcium needs) are high, and exposure to sunlight may be limited [<a href="#rid7">7-9</a>].</p><p>Risk factors for vitamin D deficiency rickets are (see  <a class="medical medical_review" href="/z/d/html/14590.html" rel="external">"Vitamin D insufficiency and deficiency in children and adolescents", section on 'Pathogenesis and risk factors'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maternal vitamin D deficiency during pregnancy</strong> – When a woman has very severe vitamin D deficiency during pregnancy, her offspring can have signs of rickets at birth or during the first three months of life [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breastfeeding</strong> – In infants from resource-abundant settings, the main reasons for inadequate vitamin D supply are prolonged breastfeeding without vitamin D supplementation and concomitant avoidance of sun exposure [<a href="#rid7">7-9</a>]. The recommended intake of vitamin D to prevent deficiency is 400 international units (10 mcg) daily in healthy infants and 600 international units (15 mcg) daily for children 1 to 18 years old [<a href="#rid11">11</a>]. Human milk typically contains less than 25 international units (0.6 mcg) of vitamin D per liter [<a href="#rid12">12-14</a>], unless the mother receives vitamin D supplementation in high doses (eg, more than 2000 international units [50 mcg] daily) [<a href="#rid15">15,16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin pigmentation and low sun exposure</strong> – Dark skin is an additional risk factor for developing rickets in breastfed infants because dark-skinned individuals produce less vitamin D in response to sunlight [<a href="#rid7">7,9,10</a>]. The vitamin D concentration of the breast milk of dark-skinned mothers is less than that of lighter-skinned individuals [<a href="#rid13">13</a>]. Most mothers of breastfed infants with rickets also are deficient in vitamin D. Thus, all at-risk mothers should be evaluated for vitamin D deficiency [<a href="#rid17">17,18</a>]. Siblings of infants with rickets should also be considered at high risk for vitamin D deficiency and should be appropriately evaluated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other causes</strong> – Other causes of vitamin D deficiency resulting from diminished absorption are cystic fibrosis or other disorders of exocrine pancreatic function, gastrectomy or extensive bowel surgery, celiac disease, inflammatory bowel disease, and other malabsorptive conditions. Certain anticonvulsants and antiretroviral drugs used to treat HIV infection can cause vitamin D deficiency by enhancing catabolism of 25OHD and 1,25-dihydroxyvitamin D (1,25[OH]<sub>2</sub>D). Obesity is associated with low serum concentrations of vitamin D, but the mechanisms and clinical significance of this association have not been established. Selective food avoidance has led to nutritional rickets in children with autism, avoidant restrictive food intake disorder, and chronic neurologic diseases [<a href="#rid19">19,20</a>].</p><p></p><p class="bulletIndent1">The effects of lockdowns during the coronavirus disease 2019 (COVID-19) pandemic have also been implicated as increasing the incidence of rickets [<a href="#rid21">21</a>].</p><p></p><p class="headingAnchor" id="H5"><span class="h3">Prevention</span><span class="headingEndMark"> — </span>In North America, infant formula, cow's milk, and cereals are fortified with vitamin D. All infant formulas in the United States contain at least 400 international units/L (10 mcg/L) of vitamin D [<a href="#rid22">22</a>]. Nonetheless, the diet of exclusively breastfed infants and of partially formula-fed infants does not provide the recommended intake of vitamin D. As a result, vitamin D supplementation is recommended for these infants. Vitamin D supplementation is also recommended for children who consume less than 1000 mL (33 oz) of vitamin D-fortified milk daily, unless they have ample regular exposure to direct sunlight. (See  <a class="medical medical_review" href="/z/d/html/14590.html" rel="external">"Vitamin D insufficiency and deficiency in children and adolescents", section on 'Prevention'</a>.)</p><p>Most nutritional rickets are prevented by adherence to these guidelines. However, infants born to mothers with severe vitamin D deficiency may rarely develop rickets, even if they are fed adequate amounts of vitamin D-fortified formula and are growing normally [<a href="#rid7">7</a>]. An increased total daily intake of up to 800 international units (20 mcg) may be necessary for premature infants, dark-skinned infants, and those who live at latitudes above 40º [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/14590.html" rel="external">"Vitamin D insufficiency and deficiency in children and adolescents", section on 'Prevention in the perinatal period and in infants'</a>.)</p><p class="headingAnchor" id="H6"><span class="h3">Clinical course</span><span class="headingEndMark"> — </span>Vitamin D deficiency rickets has three stages with increasing severity (<a class="graphic graphic_table graphicRef86780" href="/z/d/graphic/86780.html" rel="external">table 1</a>) [<a href="#rid23">23,24</a>]. Stage one is caused by impaired intestinal calcium absorption, resulting in hypocalcemia, whereas serum inorganic phosphorus is normal. Hypophosphatemia develops in stages two and three, coinciding with clinically apparent rickets. Serum calcium is normal in stage two because of a compensatory increase in parathyroid hormone (PTH) secretion but becomes low again in stage three, when the hyperparathyroidism is unable to compensate for the severe restriction in available calcium, and the clinical and radiologic findings of rickets are severe. Because later stages of the disorder are characterized by severe secondary hyperparathyroidism, hyperaminoaciduria and hyperphosphaturia may occur.</p><p>The clinical features of and diagnostic evaluation for hypocalcemic rickets are discussed separately. Of note, in settings where resources are limited, the elevation in total serum alkaline phosphatase activity (generally &gt;350 international units/L) is a very good marker for nutritional rickets in children [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/z/d/html/5856.html" rel="external">"Overview of rickets in children"</a>.)</p><p class="headingAnchor" id="H7"><span class="h3">Treatment</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Daily therapy</strong> – The most widely used treatment for vitamin D deficiency rickets consists of daily replacement doses of vitamin D2 (<a class="drug drug_pediatric" data-topicid="13274" href="/z/d/drug information/13274.html" rel="external">ergocalciferol</a>) or vitamin D3 (<a class="drug drug_pediatric" data-topicid="13086" href="/z/d/drug information/13086.html" rel="external">cholecalciferol</a>). The following dosing scheme is recommended for children without underlying defects in intestinal absorptive function:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infants &lt;1 month old</strong> – 1000 international units (25 mcg) daily for up to three months, followed by maintenance dosing of 400 international units (10 mcg) daily.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infants 1 to 12 months old</strong> – 1000 to 2000 international units (25 to 50 mcg) daily for up to three months, followed by maintenance dosing of 400 international units (10 mcg) daily.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Children 1 to 12 years</strong> – 2000 to 6000 international units (50 to 150 mcg) daily for three months, followed by maintenance dosing of 600 international units (15 mcg) daily.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Children ≥12 years old</strong> – 6000 international units (150 mcg) daily for three months, followed by maintenance dosing of 600 international units (15 mcg) daily.</p><p></p><p class="bulletIndent1">Children with malabsorption, those on medications that impact vitamin D metabolism, and obese children with vitamin D deficiency may require higher replacement doses (two to three times higher than in children without these conditions), followed by higher maintenance dosing. Dose titration may be necessary in view of the variable degrees of malabsorption and supplemental requirements.</p><p></p><p class="bulletIndent1">Treatment should also include the provision of 30 to 50 mg of elemental calcium/kg body weight per day, from dietary sources or supplements. This is particularly important in patients with elevated levels of PTH to avoid the so-called "hungry bone" syndrome (worsening hypocalcemia after the start of vitamin D therapy).</p><p></p><p class="bulletIndent1">Global Consensus Recommendations suggest somewhat higher doses for infants (vitamin D 2000 international units [50 mcg] daily) [<a href="#rid26">26</a>]. However, because of risks of inducing hypercalcemia in small infants [<a href="#rid27">27</a>], we suggest the lower doses outlined above and emphasize the need to perform biochemical monitoring and to titrate doses as indicated.</p><p></p><p class="bulletIndent1">This regimen of vitamin D and calcium supplementation should lead to resolution of the biochemical and radiologic abnormalities within three months. We repeat the biochemical evaluation within one month of starting therapy for safety reasons, and we check radiographs for evidence of healing after two to three months of treatment. (See <a class="local">'Monitoring'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stoss therapy</strong> – An alternative treatment protocol is the so-called "stoss therapy," which consists of a high dose of vitamin D given on a single day. The Global Consensus prefers daily therapy rather than stoss therapy, but recognizes that stoss therapy is sometimes more practical, and provides the following dosing recommendations, using oral vitamin D3 (<a class="drug drug_pediatric" data-topicid="13086" href="/z/d/drug information/13086.html" rel="external">cholecalciferol</a>) and not <a class="drug drug_pediatric" data-topicid="13274" href="/z/d/drug information/13274.html" rel="external">vitamin D2</a> [<a href="#rid26">26</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infants &lt;3 months of age – Stoss therapy not recommended</p><p class="bulletIndent2"><span class="glyph">•</span>Infants 3 to 12 months of age – A single dose of 50,000 international units (1250 mcg)</p><p class="bulletIndent2"><span class="glyph">•</span>Children 1 to 12 years – A single dose of 150,000 international units (3750 mcg)</p><p class="bulletIndent2"><span class="glyph">•</span>Children ≥ 12 years – A single dose of 300,000 international units (7500 mcg)</p><p></p><p class="bulletIndent1">This amount of vitamin D should be sufficient to induce healing of the growth plate within three months. Stoss therapy may be advantageous when compliance with therapy and/or follow-up is anticipated to be a problem [<a href="#rid5">5,28</a>]. However, high doses of vitamin D may lead to hypercalcemia. Finally, in older children, a modified higher-dose approach has been successfully used, particularly when there is concern about adherence to a daily regimen. The regimen consists of weekly doses of 50,000 international units (1250 mcg) of vitamin D for two to three months. Adequate calcium intake should also be assured when using stoss therapy (as with daily therapy).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamin D deficiency without rickets</strong> – Expert opinion varies regarding doses for vitamin D replacement in infants and children with serum levels of 25OHD less than 20 ng/mL (50 nmol/L) but without clinical evidence of rickets. Some authorities recommend the same dosing scheme that is used for children with rickets, as outlined above [<a href="#rid5">5</a>]. In our own practice, we tend to use somewhat lower doses (400 international units [10 mcg] daily in children less than one month of age and up to 1000 international units [25 mcg] daily for older children). We feel that this reduces the risk of inducing hypercalcemia, especially in children who may not reliably return for biochemical monitoring after one month of therapy. (See  <a class="medical medical_review" href="/z/d/html/14590.html" rel="external">"Vitamin D insufficiency and deficiency in children and adolescents", section on 'Vitamin D deficiency or insufficiency'</a>.)</p><p></p><p class="headingAnchor" id="H8"><span class="h3">Monitoring</span><span class="headingEndMark"> — </span>Serum calcium, phosphorus, alkaline phosphatase concentrations, and urinary calcium:creatinine ratio should be measured four weeks after the start of therapy in children who are being treated for vitamin D deficiency rickets. At this time, serum calcium and phosphorus levels should have normalized and alkaline phosphatase should have started to decrease towards the reference range. The urinary calcium:creatinine ratio may still be low. These tests should be repeated monthly until doses are adjusted downward to a typical daily replacement amount. This typically occurs by three months of therapy, at which time radiographs can be obtained to document the healing of rachitic lesions.</p><p>Orthopedic consultation usually is not indicated, because skeletal deformities regress completely after successful medical therapy. Correction of bow defects is a more chronic process and may take months to years to correct after the radiographic appearance of the growth plates has normalized. Orthopedic intervention may be necessary if deformities do not eventually improve.</p><p>If the radiographs do not show evidence of healing, or biochemical parameters are not improving, the possibility of poor adherence to treatment, malabsorption of vitamin D, or other forms of rickets should be considered. Consideration of an alternate diagnosis is particularly important when the original biochemical profile had borderline values. As an example, modest elevations in serum PTH are occasionally observed in X-linked hypophosphatemia, leading to an erroneous diagnosis of calcipenic rickets. (See  <a class="medical medical_review" href="/z/d/html/5856.html" rel="external">"Overview of rickets in children", section on 'Further evaluation'</a>.)</p><p>An additional biochemical parameter of the adequacy of calcium and vitamin D supplementation that may be useful in older children is the reappearance of normal levels of urinary calcium excretion, showing that the body's vitamin D and calcium stores have been replenished. If the patient has low urinary calcium excretion after three months of treatment, continuation of the same treatment regimen for another three months is advisable.</p><p>Monitoring is also important to ensure that no toxicity has occurred, particularly if the vitamin D dose was erroneously dispensed or administered. We have encountered hypercalcemia in the setting where high doses were continued for a longer duration than intended due to poor compliance with follow-up visits.</p><p class="headingAnchor" id="H9"><span class="h2">Calcium deficiency</span></p><p class="headingAnchor" id="H10"><span class="h3">Etiology</span><span class="headingEndMark"> — </span>Rickets can occur despite adequate vitamin D levels if calcium intake is very low. This problem generally does not occur unless calcium intake is very low, because vitamin D increases intestinal calcium absorption [<a href="#rid29">29,30</a>]. Most children with calcium deficiency rickets have normal serum 25OHD and high serum 1,25(OH)<sub>2</sub>D concentrations, indicating adequate intake of vitamin D. These children may have an increased vitamin D requirement when measured by their response to vitamin D replacement [<a href="#rid31">31</a>]. Thus, vitamin D requirements may be higher than expected in children who are calcium deficient [<a href="#rid32">32</a>]. Indeed, the turnover of vitamin D is accelerated in the setting of calcium deficiency; the two nutrients are inherently linked, such that limited availability of one will result in limited supply of the other. Thus, it is likely that rickets due to a combination of calcium and vitamin D deficiency accounts for many cases. This interaction between the two nutrients can be quantified: A reanalysis of data from earlier studies describing the Nigerian population with calcium deficiency (discussed below) has shown that the vitamin D requirement necessary to prevent rickets varies inversely with dietary calcium intake [<a href="#rid33">33</a>].</p><p>Calcium deficiency rickets was well documented in a randomized, double-blind, controlled trial of 123 Nigerian children with rickets [<a href="#rid34">34</a>]. In this population, the baseline intake of calcium was very low (approximately 200 mg per day) and the children responded to treatment with calcium, with or without vitamin D [<a href="#rid34">34</a>]. However, other factors in addition to calcium intake must play a role because control children without rickets had similarly low calcium intake [<a href="#rid35">35</a>]; this may include mutations in <em>CYP2R1</em>, which encodes the principal vitamin D 25-hydroxylase (see <a class="local">'25-hydroxylase deficiency'</a> below). Although most of the studies on calcium deficiency rickets were performed in Africa, similar dietary deficiencies occur in North America [<a href="#rid30">30,36-38</a>].</p><p>Interestingly, rickets does not often occur in typical primary hypoparathyroidism, perhaps in view of elevated phosphorus levels or a possible role of PTH in mediating the growth plate lesion. (See  <a class="medical medical_review" href="/z/d/html/5846.html" rel="external">"Etiology of hypocalcemia in infants and children", section on 'Hypocalcemia with low PTH (hypoparathyroidism)'</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>As shown by the study of Nigerian children described above [<a href="#rid34">34</a>], calcium deficiency rickets can be treated by ensuring a daily intake of 1000 mg of calcium and maintenance of vitamin D intake at the recommended daily value.</p><p class="headingAnchor" id="H1406346080"><span class="h1">DEFECTS IN VITAMIN D METABOLISM</span><span class="headingEndMark"> — </span>Vitamin D from the diet or dermal synthesis is biologically inactive and requires enzymatic conversion in the liver and kidney to the active metabolite, 1,25-dihydroxyvitamin D (1,25[OH]<sub>2</sub>D) (<a class="graphic graphic_figure graphicRef65360" href="/z/d/graphic/65360.html" rel="external">figure 1</a>). Physiologic or genetic disturbances in this process may lead to vitamin D deficiency and rickets, often with hypocalcemia and compensatory parathyroid hormone (PTH) secretion.</p><p class="headingAnchor" id="H665523223"><span class="h2">Hepatic or renal dysfunction</span><span class="headingEndMark"> — </span>Patients with severe liver disease may have impaired 25-hydroxylation of vitamin D. Some drugs, including certain anticonvulsants, also reduce available 25-hydroxylated vitamin D by increasing its catabolism. Similarly, renal failure may interfere with normal renal formation of 1,25(OH)<sub>2</sub>D. (See  <a class="medical medical_review" href="/z/d/html/5846.html" rel="external">"Etiology of hypocalcemia in infants and children", section on 'Hepatic dysfunction'</a> and  <a class="medical medical_review" href="/z/d/html/5846.html" rel="external">"Etiology of hypocalcemia in infants and children", section on 'Renal dysfunction'</a>.)</p><p class="headingAnchor" id="H997925346"><span class="h2">Genetic disorders</span></p><p class="headingAnchor" id="H172616220"><span class="h3">25-hydroxylase deficiency</span><span class="headingEndMark"> — </span>Mutations in <em>CYP2R1</em>, the gene that encodes the enzyme principally responsible for 25-hydroxylation of vitamin D, causes a form of "hydroxylation-deficient" rickets (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F600081&amp;token=87jLzclRwWxNoI%2BQq5Gg790GCJ0HqNejgXFDB2kMViEE2pIjTL8U%2FUqfE8yB1mOZ&amp;TOPIC_ID=5804" target="_blank">MIM #600081</a>). This disorder is exceedingly rare and has been described in only a few case reports [<a href="#rid39">39-41</a>]. In a Nigerian population, individuals with heterozygous <em>CYP2R1</em> mutation are distinguished by rickets that responds more effectively to calcium rather than vitamin D supplementation and by a familial pattern of inheritance [<a href="#rid39">39</a>]. Individuals with homozygous mutations of <em>CYP2R1</em> show modest responses to high-dose vitamin D supplementation (as <a class="drug drug_pediatric" data-topicid="13274" href="/z/d/drug information/13274.html" rel="external">ergocalciferol</a> or <a class="drug drug_pediatric" data-topicid="13086" href="/z/d/drug information/13086.html" rel="external">cholecalciferol</a>) or calcium [<a href="#rid40">40</a>] and theoretically would respond well to physiologic doses of 25-hydroxyvitamin D. Nevertheless, phenotypes and severity vary [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H266914855"><span class="h3">1-alpha-hydroxylase deficiency</span><span class="headingEndMark"> — </span>1-alpha-hydroxylase deficiency (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F264700&amp;token=87jLzclRwWxNoI%2BQq5Gg704lyzSCGyCZfNK54Celwnu8Ez0t6zWcaecAkQb2Js7T&amp;TOPIC_ID=5804" target="_blank">MIM #264700</a>) is a somewhat more common form of vitamin D-resistant rickets, first identified in 1961 [<a href="#rid42">42</a>]. It was previously known as pseudovitamin D deficiency rickets, or vitamin D-dependent rickets type I because of its "dependence" on pharmacologic dosing of vitamin D.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology</strong> – 1-alpha-hydroxylase deficiency, an autosomal recessive disorder, is characterized by defective conversion of 25-hydroxyvitamin D (25OHD) to 1,25(OH)<sub>2</sub>D [<a href="#rid43">43</a>]. The characteristic biochemical findings of 1-alpha-hydroxylase deficiency are normal serum levels of 25OHD and low levels of 1,25(OH)<sub>2</sub>D (<a class="graphic graphic_table graphicRef81032" href="/z/d/graphic/81032.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1">Patients with 1-alpha-hydroxylase deficiency have inactivating mutations in the<em> CYP27B1</em> gene [<a href="#rid44">44-46</a>], which encodes the enzyme (25-hydroxyvitamin D 1-alpha-hydroxylase or, simply, 1-alpha-hydroxylase) responsible for the conversion of 25OHD to 1,25(OH<sub>)2</sub>D. Mice with inactivation of the gene encoding 1-alpha-hydroxylase mimic the 1-alpha-hydroxylase deficiency phenotype [<a href="#rid47">47,48</a>]. Mutation analysis of the<em> CYP27B1</em> gene can confirm the diagnosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – 1-alpha-hydroxylase deficiency is characterized by early onset of skeletal disease (within the first year of life) and severe hypocalcemia (sometimes with tetany) and secondary hyperparathyroidism with modest to moderate hypophosphatemia. Enamel hypoplasia may occur. These features differ from those encountered in X-linked hypophosphatemic rickets (previously known as X-linked vitamin D-resistant rickets), which is characterized by markedly low serum phosphorus and a normal or slightly elevated serum PTH level, and serum calcium is usually normal prior to treatment. Although the condition is somewhat rare, it continues to be regularly identified; the author is aware of this disorder being occasionally misdiagnosed as X-linked hypophosphatemia. (See  <a class="medical medical_review" href="/z/d/html/5802.html" rel="external">"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia", section on 'X-linked hypophosphatemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – The treatment for 1-alpha-hydroxylase deficiency is replacement therapy with the activated vitamin D metabolite, 1,25(OH)<sub>2</sub>D<sub>3</sub> (<a class="drug drug_pediatric" data-topicid="13107" href="/z/d/drug information/13107.html" rel="external">calcitriol</a>), an off-label use of this drug [<a href="#rid46">46</a>]. The dose depends upon the severity of disease and the child's body weight. A suggested initial dose for florid rickets is 1 mcg daily. Treatment is continued at this dose until bones are healed. Thereafter, the maintenance dose varies between 0.2 and 2 mcg daily, depending on the results of biochemical analyses, as described in the next paragraph. The aims of the treatment are to achieve normal serum calcium levels, maintain PTH levels within normal limits, and avoid hypercalciuria [<a href="#rid46">46</a>]. It is important to maintain adequate intake of dietary calcium (30 to 75 mg/kg daily of elemental calcium). An alternative approach that is more readily available than calcitriol in some countries is 1-alpha-OHD<sub>3</sub> (<a class="drug drug_general" data-topicid="16467" href="/z/d/drug information/16467.html" rel="external">alfacalcidol</a>), used in doses of 1 to 3 mcg daily [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – Close supervision is needed during the initial phase of treatment, including a physical examination and biochemical evaluation every two to three weeks. The biochemical evaluation should include measurement of serum calcium, phosphorus, alkaline phosphatase, and PTH levels. Radiographs should show clear improvement after four weeks of therapy and should be repeated after three months, when the growth plates should have regained a normal appearance. Patients may be evaluated at three-month intervals during maintenance therapy. Hand radiographs are performed once per year to check for the reappearance of rachitic changes.</p><p></p><p class="bulletIndent1">Possible side effects of 1,25(OH)<sub>2</sub>D<sub>3</sub> therapy include hypercalcemia, hypercalciuria, nephrocalcinosis, and intraocular calcifications [<a href="#rid46">46</a>]. Therefore, it is important to monitor the urinary calcium:creatinine ratio and kidney function (eg, serum creatinine) at each visit. Renal ultrasound should be performed once per year. Ophthalmic consultation and slit-lamp examination should be considered if manifestations of chronic hypercalcemia are evident, such as nephrocalcinosis.</p><p></p><p class="headingAnchor" id="H3866075834"><span class="h3">Increased catabolism of vitamin D</span><span class="headingEndMark"> — </span>Gain-of-function variants in <em>CYP3A4</em>, the gene encoding a vitamin D catabolic enzyme, cause increased degradation of both 25OHD and the active 1,25(OH)<sub>2</sub>D metabolite. Patients with this apparently exceedingly rare mutation have low circulating levels of both 25OHD and 1,25(OH)<sub>2</sub>D, indicating genetic dysregulation of vitamin D catabolism [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H2968463276"><span class="h1">DEFECT IN VITAMIN D ACTION</span></p><p class="headingAnchor" id="H16"><span class="h2">Hereditary resistance to vitamin D</span><span class="headingEndMark"> — </span>Hereditary resistance to vitamin D (HRVD) was previously called vitamin D-dependent rickets type II and is characterized by end-organ resistance to vitamin D [<a href="#rid51">51</a>]. It is another rare form of rickets.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology</strong> – HRVD is an autosomal recessive disorder. It is associated with end–organ resistance to 1,25-dihydroxyvitamin D (1,25[OH]<sub>2</sub>D), usually caused by mutations in the gene encoding the vitamin D receptor. The defect in the receptor interferes with the function of the hormone-receptor complex, thereby preventing 1,25(OH)<sub>2</sub>D action [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – The clinical spectrum of HRVD varies widely, probably reflecting the type of mutation within the vitamin D receptor and the amount of residual vitamin D receptor activity. Affected children usually appear normal at birth but develop rickets within the first two years of life. Alopecia and ectodermal anomalies resulting from the lack of vitamin D receptor activity within keratinocytes develops in approximately two-thirds of cases and is a marker of disease severity (HRVD type 2A, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F277440&amp;token=87jLzclRwWxNoI%2BQq5Gg7%2B4WWa4cHSTVg9AumYDSGOyHR0lc2wu0d082Un75MqPx&amp;TOPIC_ID=5804" target="_blank">MIM #277440</a>) [<a href="#rid52">52,53</a>]. Other patients have the classical rickets phenotype but without alopecia or other ectodermal anomalies; some of these patients have been found to abnormally express a hormone response element-binding protein that interferes with the normal function of the vitamin D receptor (HRVD type 2B, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F600785&amp;token=87jLzclRwWxNoI%2BQq5Gg7wIqIF1agpPyD%2BepWXXTbTYKCNJMb6YxlbAk%2FITG2r8M&amp;TOPIC_ID=5804" target="_blank">MIM %600785</a>). In view of the rarity of the condition and the specialized management required, genetic testing for these conditions is recommended.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – The treatment of HRVD involves a therapeutic trial of 1,25(OH)<sub>2</sub>D (<a class="drug drug_pediatric" data-topicid="13107" href="/z/d/drug information/13107.html" rel="external">calcitriol</a>) and calcium supplementation. The individual response is difficult to predict because the severity of the receptor defect varies among patients. Therapy may start at daily doses of 2 mcg of 1,25(OH)<sub>2</sub>D and 1000 mg of elemental calcium. However, administration of extremely high doses of 1,25(OH)<sub>2</sub>D (up to 30 to 60 mcg daily) and calcium (up to 3 g daily) may be necessary to restore normocalcemia and mineralize depleted bones.</p><p></p><p class="bulletIndent1">Long-term infusion of calcium into a central vein is a possible alternative therapeutic option for severely resistant patients [<a href="#rid54">54,55</a>]. Although early regimens were given for many months, reports indicate that brief, intermittent intravenous infusions may be effective [<a href="#rid56">56</a>]. Oral calcium therapy may be sufficient once radiographic healing has been observed [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – During treatment, patients should initially be evaluated at least once per week. Serum concentrations of calcium, phosphorus, alkaline phosphatase, creatinine, 1,25(OH)<sub>2</sub>D, and parathyroid hormone (PTH) and the urinary calcium:creatinine ratio should be measured.</p><p></p><p class="bulletIndent1">If the biochemical parameters do not respond, the dose of 1,25(OH)<sub>2</sub>D should be gradually increased to reach serum concentrations of up to 100 times the normal mean value. Failure of therapy should be considered if no biochemical response occurs after three to five months of treatment.</p><p></p><p class="headingAnchor" id="H2896459391"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110420.html" rel="external">"Society guideline links: Vitamin D deficiency"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/111342.html" rel="external">"Society guideline links: Pediatric bone health"</a>.)</p><p class="headingAnchor" id="H367663598"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/86460.html" rel="external">"Patient education: Vitamin D for babies and children (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H33081921"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and categorization</strong> – Calcipenic rickets comprises a group of disorders in which intestinal absorption of calcium is insufficient to match the calcium requirements for bone growth. Calcipenic rickets is characterized by elevated parathyroid hormone (PTH) and normal or low serum inorganic phosphorus concentrations (<a class="graphic graphic_algorithm graphicRef79880" href="/z/d/graphic/79880.html" rel="external">algorithm 1</a>) and may have concomitant hypocalcemia. Measurement of the serum 25-hydroxyvitamin D (25OHD) level helps to identify the cause (<a class="graphic graphic_algorithm graphicRef80602" href="/z/d/graphic/80602.html" rel="external">algorithm 2</a> and <a class="graphic graphic_table graphicRef81032" href="/z/d/graphic/81032.html" rel="external">table 2</a>). (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamin D deficiency</strong> <strong>rickets</strong> – Vitamin D deficiency rickets usually presents between three months and three years of age, when growth rates (and calcium needs) are high. The main reasons for inadequate vitamin D supply in infants from resource-abundant settings are prolonged breastfeeding without vitamin D supplementation and concomitant avoidance of sun exposure. Vitamin D deficiency may also be caused by malabsorptive conditions. (See <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prevention</strong> – To prevent vitamin D deficiency, vitamin D supplementation is recommended for all breastfed infants. Older children also may require supplements depending on their dietary sources of vitamin D and sun exposure. (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment</strong> – Infants and children with any stage of vitamin D deficiency rickets should be treated with vitamin D. We use oral vitamin D2 (<a class="drug drug_pediatric" data-topicid="13274" href="/z/d/drug information/13274.html" rel="external">ergocalciferol</a>) or D3 (<a class="drug drug_pediatric" data-topicid="13086" href="/z/d/drug information/13086.html" rel="external">cholecalciferol</a>); a variety of dosing schemes are effective. For patients with elevated levels of PTH, an oral calcium supplement should be prescribed to avoid "hungry bone" syndrome. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Subclinical vitamin D deficiency</strong> – We also suggest vitamin D replacement for infants and children with serum levels of 25OHD less than 20 ng/mL (50 nmol/L) but without clinical evidence of rickets (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For these children with subclinical vitamin D deficiency, we use replacement doses of 400 international units (10 mcg) daily in children less than one month of age and up to 1000 international units (25 mcg) daily for older children. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monitoring</strong> – During treatment for vitamin D deficiency rickets, children should be monitored with laboratory tests and radiographs should be obtained to document healing of rachitic lesions (see <a class="local">'Monitoring'</a> above). Children who do not respond despite adherence to treatment may have a defect in vitamin D absorption or metabolism, or increased catabolism. (See <a class="local">'Genetic disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calcium deficiency rickets</strong> – Less commonly, dietary deficiency of calcium may cause nutritional rickets. This is suggested by the presence of rickets in countries where the incidence of hypocalcemic rickets is high, despite ample sunlight and adequate exposure to the sunlight (in the absence of sunscreen) and normal serum concentrations of vitamin D. Because children who are calcium deficient may have higher than expected requirements for vitamin D, they should be treated with both calcium and vitamin D supplementation. Many cases are likely due to combined deficiencies of calcium and vitamin D. (See <a class="local">'Calcium deficiency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic causes of calcipenic rickets</strong> – Genetic causes of calcipenic rickets include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Deficiencies of 25-hydroxylase or 1-alpha hydroxylase, the enzymes responsible for conversion of vitamin D to the active form</p><p class="bulletIndent2"><span class="glyph">•</span>Increased catabolism of 25OHD caused by gain-of-function variants in <em>CYP3A4</em></p><p class="bulletIndent2"><span class="glyph">•</span>Hereditary resistance to vitamin D due to end–organ resistance</p><p></p><p class="bulletIndent1">These disorders can be distinguished by characteristic biochemical findings (<a class="graphic graphic_table graphicRef81032" href="/z/d/graphic/81032.html" rel="external">table 2</a>) and confirmed by genetic testing. (See <a class="local">'Genetic disorders'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Fischer PR, Thacher TD, Pettifor JM. Pediatric vitamin D and calcium nutrition in developing countries. Rev Endocr Metab Disord 2008; 9:181.</a></li><li><a class="nounderline abstract_t">Muhe L, Lulseged S, Mason KE, Simoes EA. Case-control study of the role of nutritional rickets in the risk of developing pneumonia in Ethiopian children. Lancet 1997; 349:1801.</a></li><li><a class="nounderline abstract_t">Holland PC, Wilkinson AR, Diez J, Lindsell DR. Prenatal deficiency of phosphate, phosphate supplementation, and rickets in very-low-birthweight infants. Lancet 1990; 335:697.</a></li><li><a class="nounderline abstract_t">Gonzalez Ballesteros LF, Ma NS, Gordon RJ, et al. Unexpected widespread hypophosphatemia and bone disease associated with elemental formula use in infants and children. Bone 2017; 97:287.</a></li><li><a class="nounderline abstract_t">Misra M, Pacaud D, Petryk A, et al. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics 2008; 122:398.</a></li><li><a class="nounderline abstract_t">Thandrayen K, Pettifor JM. Maternal vitamin D status: implications for the development of infantile nutritional rickets. Endocrinol Metab Clin North Am 2010; 39:303.</a></li><li><a class="nounderline abstract_t">Ward LM, Gaboury I, Ladhani M, Zlotkin S. Vitamin D-deficiency rickets among children in Canada. CMAJ 2007; 177:161.</a></li><li><a class="nounderline abstract_t">Robinson PD, Högler W, Craig ME, et al. The re-emerging burden of rickets: a decade of experience from Sydney. Arch Dis Child 2006; 91:564.</a></li><li><a class="nounderline abstract_t">Beck-Nielsen SS, Jensen TK, Gram J, et al. Nutritional rickets in Denmark: a retrospective review of children's medical records from 1985 to 2005. Eur J Pediatr 2009; 168:941.</a></li><li><a class="nounderline abstract_t">Hatun S, Ozkan B, Orbak Z, et al. Vitamin D deficiency in early infancy. J Nutr 2005; 135:279.</a></li><li><a class="nounderline abstract_t">Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011; 96:53.</a></li><li><a class="nounderline abstract_t">Reeve LE, Chesney RW, DeLuca HF. Vitamin D of human milk: identification of biologically active forms. Am J Clin Nutr 1982; 36:122.</a></li><li><a class="nounderline abstract_t">Specker BL, Tsang RC, Hollis BW. Effect of race and diet on human-milk vitamin D and 25-hydroxyvitamin D. Am J Dis Child 1985; 139:1134.</a></li><li><a class="nounderline abstract_t">Hollis BW, Roos BA, Draper HH, Lambert PW. Vitamin D and its metabolites in human and bovine milk. J Nutr 1981; 111:1240.</a></li><li><a class="nounderline abstract_t">Hollis BW, Wagner CL. Vitamin D requirements during lactation: high-dose maternal supplementation as therapy to prevent hypovitaminosis D for both the mother and the nursing infant. Am J Clin Nutr 2004; 80:1752S.</a></li><li><a class="nounderline abstract_t">Wagner CL, Hulsey TC, Fanning D, et al. High-dose vitamin D3 supplementation in a cohort of breastfeeding mothers and their infants: a 6-month follow-up pilot study. Breastfeed Med 2006; 1:59.</a></li><li><a class="nounderline abstract_t">Nozza JM, Rodda CP. Vitamin D deficiency in mothers of infants with rickets. Med J Aust 2001; 175:253.</a></li><li><a class="nounderline abstract_t">Dawodu A, Agarwal M, Sankarankutty M, et al. Higher prevalence of vitamin D deficiency in mothers of rachitic than nonrachitic children. J Pediatr 2005; 147:109.</a></li><li><a class="nounderline abstract_t">Hartman JS, Silver AH. Nutritional Rickets Due to Severe Food Selectivity in Autism Spectrum Disorder. J Dev Behav Pediatr 2021; 42:66.</a></li><li><a class="nounderline abstract_t">Islam N, Hathaway KL, Anderson BS, et al. Brief Report: Decreased Bone Health in Children with Autism Spectrum Disorder and Avoidant Restrictive Food Intake Disorder. J Autism Dev Disord 2023.</a></li><li><a class="nounderline abstract_t">Sodri NI, Mohamed-Yassin MS, Mohd Nor NS, Ismail IA. Rickets Due to Severe Vitamin D and Calcium Deficiency During the COVID-19 Pandemic in Malaysia. Am J Case Rep 2021; 22:e934216.</a></li><li class="breakAll">Nutrition During Infancy: Principles and Practice, 2nd ed, Tsang RC, Zlotkin SH, Nichols BL, Hansen JW (Eds), Digital Education Publishing, 1997. p.467.</li><li><a class="nounderline abstract_t">Fraser D, Kooh SW, Scriver CR. Hyperparathyroidism as the cause of hyperaminoaciduria and phosphaturia in human vitamin D deficiency. Pediatr Res 1967; 1:425.</a></li><li><a class="nounderline abstract_t">Kruse K. Pathophysiology of calcium metabolism in children with vitamin D-deficiency rickets. J Pediatr 1995; 126:736.</a></li><li><a class="nounderline abstract_t">Thacher TD, Sempos CT, Durazo-Arvizu RA, et al. The Validity of Serum Alkaline Phosphatase to Identify Nutritional Rickets in Nigerian Children on a Calcium-Deprived Diet. J Clin Endocrinol Metab 2021; 106:e3559.</a></li><li><a class="nounderline abstract_t">Munns CF, Shaw N, Kiely M, et al. Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. J Clin Endocrinol Metab 2016; 101:394.</a></li><li><a class="nounderline abstract_t">Vanstone MB, Oberfield SE, Shader L, et al. Hypercalcemia in children receiving pharmacologic doses of vitamin D. Pediatrics 2012; 129:e1060.</a></li><li><a class="nounderline abstract_t">Munns C, Zacharin MR, Rodda CP, et al. Prevention and treatment of infant and childhood vitamin D deficiency in Australia and New Zealand: a consensus statement. Med J Aust 2006; 185:268.</a></li><li><a class="nounderline abstract_t">Pfitzner MA, Thacher TD, Pettifor JM, et al. Absence of vitamin D deficiency in young Nigerian children. J Pediatr 1998; 133:740.</a></li><li><a class="nounderline abstract_t">DeLucia MC, Mitnick ME, Carpenter TO. Nutritional rickets with normal circulating 25-hydroxyvitamin D: a call for reexamining the role of dietary calcium intake in North American infants. J Clin Endocrinol Metab 2003; 88:3539.</a></li><li><a class="nounderline abstract_t">Thacher TD, Fischer PR, Isichei CO, Pettifor JM. Early response to vitamin D2 in children with calcium deficiency rickets. J Pediatr 2006; 149:840.</a></li><li><a class="nounderline abstract_t">Thacher TD, Fischer PR, Pettifor JM. Vitamin D treatment in calcium-deficiency rickets: a randomised controlled trial. Arch Dis Child 2014; 99:807.</a></li><li><a class="nounderline abstract_t">Sempos CT, Durazo-Arvizu RA, Fischer PR, et al. Serum 25-hydroxyvitamin D requirements to prevent nutritional rickets in Nigerian children on a low-calcium diet-a multivariable reanalysis. Am J Clin Nutr 2021; 114:231.</a></li><li><a class="nounderline abstract_t">Thacher TD, Fischer PR, Pettifor JM, et al. A comparison of calcium, vitamin D, or both for nutritional rickets in Nigerian children. N Engl J Med 1999; 341:563.</a></li><li><a class="nounderline abstract_t">Thacher TD, Fischer PR, Pettifor JM, et al. Case-control study of factors associated with nutritional rickets in Nigerian children. J Pediatr 2000; 137:367.</a></li><li><a class="nounderline abstract_t">Bergstrom WH. When you see rickets, consider calcium deficiency. J Pediatr 1998; 133:722.</a></li><li><a class="nounderline abstract_t">Maltz HE, Fish MB, Holliday MA. Calcium deficiency rickets and the renal response to calcium infusion. Pediatrics 1970; 46:865.</a></li><li><a class="nounderline abstract_t">Kooh SW, Fraser D, Reilly BJ, et al. Rickets due to calcium deficiency. N Engl J Med 1977; 297:1264.</a></li><li><a class="nounderline abstract_t">Thacher TD, Fischer PR, Singh RJ, et al. CYP2R1 Mutations Impair Generation of 25-hydroxyvitamin D and Cause an Atypical Form of Vitamin D Deficiency. J Clin Endocrinol Metab 2015; 100:E1005.</a></li><li><a class="nounderline abstract_t">Cheng JB, Levine MA, Bell NH, et al. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci U S A 2004; 101:7711.</a></li><li><a class="nounderline abstract_t">Ozden A, Doneray H, Turkyilmaz A. Two novel CYP2R1 mutations in a family with vitamin D-dependent rickets type 1b. Endocrine 2021; 72:852.</a></li><li><a class="nounderline abstract_t">PRADER A, ILLIG R, HEIERLI E. [An unusual form of primary vitamin D-resistant rickets with hypocalcemia and autosomal-dominant hereditary transmission: hereditary pseudo-deficiency rickets]. Helv Paediatr Acta 1961; 16:452.</a></li><li><a class="nounderline abstract_t">Fraser D, Kooh SW, Kind HP, et al. Pathogenesis of hereditary vitamin-D-dependent rickets. An inborn error of vitamin D metabolism involving defective conversion of 25-hydroxyvitamin D to 1 alpha,25-dihydroxyvitamin D. N Engl J Med 1973; 289:817.</a></li><li><a class="nounderline abstract_t">Kitanaka S, Takeyama K, Murayama A, et al. Inactivating mutations in the 25-hydroxyvitamin D3 1alpha-hydroxylase gene in patients with pseudovitamin D-deficiency rickets. N Engl J Med 1998; 338:653.</a></li><li><a class="nounderline abstract_t">Kim CJ, Kaplan LE, Perwad F, et al. Vitamin D 1alpha-hydroxylase gene mutations in patients with 1alpha-hydroxylase deficiency. J Clin Endocrinol Metab 2007; 92:3177.</a></li><li><a class="nounderline abstract_t">Edouard T, Alos N, Chabot G, et al. Short- and long-term outcome of patients with pseudo-vitamin D deficiency rickets treated with calcitriol. J Clin Endocrinol Metab 2011; 96:82.</a></li><li><a class="nounderline abstract_t">Dardenne O, Prud'homme J, Arabian A, et al. Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. Endocrinology 2001; 142:3135.</a></li><li><a class="nounderline abstract_t">Panda DK, Miao D, Tremblay ML, et al. Targeted ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci U S A 2001; 98:7498.</a></li><li><a class="nounderline abstract_t">Reade TM, Scriver CR, Glorieux FH, et al. Response to crystalline 1alpha-hydroxyvitamin D3 in vitamin D dependency. Pediatr Res 1975; 9:593.</a></li><li><a class="nounderline abstract_t">Roizen JD, Li D, O'Lear L, et al. CYP3A4 mutation causes vitamin D-dependent rickets type 3. J Clin Invest 2018; 128:1913.</a></li><li><a class="nounderline abstract_t">Malloy PJ, Feldman D. Genetic disorders and defects in vitamin d action. Endocrinol Metab Clin North Am 2010; 39:333.</a></li><li><a class="nounderline abstract_t">Sakai Y, Kishimoto J, Demay MB. Metabolic and cellular analysis of alopecia in vitamin D receptor knockout mice. J Clin Invest 2001; 107:961.</a></li><li><a class="nounderline abstract_t">Chen CH, Sakai Y, Demay MB. Targeting expression of the human vitamin D receptor to the keratinocytes of vitamin D receptor null mice prevents alopecia. Endocrinology 2001; 142:5386.</a></li><li><a class="nounderline abstract_t">Balsan S, Garabédian M, Larchet M, et al. Long-term nocturnal calcium infusions can cure rickets and promote normal mineralization in hereditary resistance to 1,25-dihydroxyvitamin D. J Clin Invest 1986; 77:1661.</a></li><li><a class="nounderline abstract_t">Hochberg Z, Tiosano D, Even L. Calcium therapy for calcitriol-resistant rickets. J Pediatr 1992; 121:803.</a></li><li><a class="nounderline abstract_t">Abalı S, Tamura M, Turan S, et al. Hereditary vitamin D-resistant rickets: a report of four cases with two novel variants in the VDR gene and successful use of intermittent intravenous calcium via a peripheral route. J Pediatr Endocrinol Metab 2020; 33:557.</a></li></ol></div><div id="topicVersionRevision">Topic 5804 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18604643" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pediatric vitamin D and calcium nutrition in developing countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9269215" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Case-control study of the role of nutritional rickets in the risk of developing pneumonia in Ethiopian children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1969066" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prenatal deficiency of phosphate, phosphate supplementation, and rickets in very-low-birthweight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28167344" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Unexpected widespread hypophosphatemia and bone disease associated with elemental formula use in infants and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18676559" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Vitamin D deficiency in children and its management: review of current knowledge and recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20511053" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Maternal vitamin D status: implications for the development of infantile nutritional rickets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17600035" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Vitamin D-deficiency rickets among children in Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15956045" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The re-emerging burden of rickets: a decade of experience from Sydney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18985384" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Nutritional rickets in Denmark: a retrospective review of children's medical records from 1985 to 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15671226" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Vitamin D deficiency in early infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21118827" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7091022" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Vitamin D of human milk: identification of biologically active forms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2998180" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effect of race and diet on human-milk vitamin D and 25-hydroxyvitamin D.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6788913" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Vitamin D and its metabolites in human and bovine milk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15585800" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Vitamin D requirements during lactation: high-dose maternal supplementation as therapy to prevent hypovitaminosis D for both the mother and the nursing infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17661565" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : High-dose vitamin D3 supplementation in a cohort of breastfeeding mothers and their infants: a 6-month follow-up pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11587256" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Vitamin D deficiency in mothers of infants with rickets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16027707" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Higher prevalence of vitamin D deficiency in mothers of rachitic than nonrachitic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32890122" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Nutritional Rickets Due to Severe Food Selectivity in Autism Spectrum Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37179523" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Brief Report: Decreased Bone Health in Children with Autism Spectrum Disorder and Avoidant Restrictive Food Intake Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34723934" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Rickets Due to Severe Vitamin D and Calcium Deficiency During the COVID-19 Pandemic in Malaysia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34723934" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Rickets Due to Severe Vitamin D and Calcium Deficiency During the COVID-19 Pandemic in Malaysia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5583448" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hyperparathyroidism as the cause of hyperaminoaciduria and phosphaturia in human vitamin D deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7751997" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pathophysiology of calcium metabolism in children with vitamin D-deficiency rickets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33982091" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The Validity of Serum Alkaline Phosphatase to Identify Nutritional Rickets in Nigerian Children on a Calcium-Deprived Diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26745253" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Global Consensus Recommendations on Prevention and Management of Nutritional Rickets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22412034" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Hypercalcemia in children receiving pharmacologic doses of vitamin D.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16948623" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Prevention and treatment of infant and childhood vitamin D deficiency in Australia and New Zealand: a consensus statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9842036" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Absence of vitamin D deficiency in young Nigerian children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12915633" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Nutritional rickets with normal circulating 25-hydroxyvitamin D: a call for reexamining the role of dietary calcium intake in North American infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17137904" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Early response to vitamin D2 in children with calcium deficiency rickets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24748637" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Vitamin D treatment in calcium-deficiency rickets: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33742199" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Serum 25-hydroxyvitamin D requirements to prevent nutritional rickets in Nigerian children on a low-calcium diet-a multivariable reanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10451461" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A comparison of calcium, vitamin D, or both for nutritional rickets in Nigerian children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10969262" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Case-control study of factors associated with nutritional rickets in Nigerian children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9842031" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : When you see rickets, consider calcium deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5491440" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Calcium deficiency rickets and the renal response to calcium infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/917072" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Rickets due to calcium deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25942481" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : CYP2R1 Mutations Impair Generation of 25-hydroxyvitamin D and Cause an Atypical Form of Vitamin D Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15128933" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33715104" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Two novel CYP2R1 mutations in a family with vitamin D-dependent rickets type 1b.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14488440" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : [An unusual form of primary vitamin D-resistant rickets with hypocalcemia and autosomal-dominant hereditary transmission: hereditary pseudo-deficiency rickets].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4357855" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pathogenesis of hereditary vitamin-D-dependent rickets. An inborn error of vitamin D metabolism involving defective conversion of 25-hydroxyvitamin D to 1 alpha,25-dihydroxyvitamin D.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9486994" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Inactivating mutations in the 25-hydroxyvitamin D3 1alpha-hydroxylase gene in patients with pseudovitamin D-deficiency rickets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17488797" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Vitamin D 1alpha-hydroxylase gene mutations in patients with 1alpha-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20926527" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Short- and long-term outcome of patients with pseudo-vitamin D deficiency rickets treated with calcitriol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11416036" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11416220" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Targeted ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1161348" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Response to crystalline 1alpha-hydroxyvitamin D3 in vitamin D dependency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29461981" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : CYP3A4 mutation causes vitamin D-dependent rickets type 3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20511055" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Genetic disorders and defects in vitamin d action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11306599" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Metabolic and cellular analysis of alopecia in vitamin D receptor knockout mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11713240" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Targeting expression of the human vitamin D receptor to the keratinocytes of vitamin D receptor null mice prevents alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3009551" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Long-term nocturnal calcium infusions can cure rickets and promote normal mineralization in hereditary resistance to 1,25-dihydroxyvitamin D.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1331389" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Calcium therapy for calcitriol-resistant rickets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32049653" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Hereditary vitamin D-resistant rickets: a report of four cases with two novel variants in the VDR gene and successful use of intermittent intravenous calcium via a peripheral route.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
